When Does the HHS Six-Peptide Comment Window Close, and What Happens Next?

What Is Open for Comment, and Until When?

On 28 October 2026 HHS announced an enforcement-discretion policy covering six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.[1][2] Our original summary covers the announcement itself. What has changed since is procedural: secondary reporting says the notice was published in the Federal Register on 30 October 2026 and carries a two-week comment period.[3] That would put the close at about 13 November 2026.

We could not retrieve the Federal Register text from our publishing environment, and none of the sources we read states the deadline outright. Treat 13 November as our arithmetic from reported dates, and verify it against the notice and its docket before relying on it. Reporting also describes the document as a draft that is not binding on HHS or the public.[4]

Where Does a Comment Window Sit in the Process?

Three separate US steps are easy to conflate. The table sets out what each does, based on how the reporting describes them.[2][4]

A comment period on an interim policy is not the same as the comment period on a proposed rule. Closing it does not finalise anything by itself; it lets the agency read submissions before deciding whether to revise, finalise or withdraw the policy. No timetable for that decision has been published.

Why Is the Comment Record Likely to Be Contested?

The July advisory committee backed the six substances, but reporting says FDA scientific staff opposed the effort and had significant safety concerns.[5][6] Our PCAC vote outcome guide and panel industry-ties guide cover that disagreement. For researchers, the useful point is evidentiary: the published literature on these peptides remains largely preclinical or small-scale, as set out in our injectable peptide evidence review. A policy decision does not add trial data.

Does This Change UK Research-Reagent Rules?

No. Section 503A governs US pharmacies preparing compounded drugs, and one report on the policy notes it has no legal effect in the United Kingdom.[7] The MHRA's separate review of UK peptide clinics turns on whether medicinal claims are made, which is covered in our MHRA clinics investigation guide. None of the six compounds holds a UK or US marketing authorisation. See are research peptides legal in the UK? for the reagent position.

How Should Researchers Keep Pharma Development and Research Reagents Apart?

Keep three categories distinct in lab records and citations. Licensed pharmaceutical development covers compounds such as retatrutide, an investigational Lilly molecule still in regulatory preparation with no marketing authorisation anywhere. US pharmacy compounding policy is the subject of this article and concerns pharmacies, not laboratories. Research reagents are supplied for in vitro work, where the relevant questions are identity, purity and traceability: HPLC and mass-spectrometry data, certificates of analysis and batch records. Our guides on reading a certificate of analysis and how peptides are tested cover those checks.

Watch three things next: the close of the comment period, any revised or final policy text, and a proposed rule for the bulks list. Our regulated peptide marketplace timeline tracks the sequence.

Compounds are supplied by Velox Peptides as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions